ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, was discovered and developed in-house utilizing Ascletis' Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and ...
To derive blood pressure, the device measures the time-of-flight between ultrasound echoes reflected from the anterior and posterior arterial walls. This time interval is converte ...
The Food and Drug Administration (FDA) has approved Tecentriq Hybreza ™ (atezolizumab and hyaluronidase-tqjs) for subcutaneous (SC) injection, for all the approved adult indications of intravenous ...
AstraZeneca is seeking approval of a subcutaneous formulation of anifrolumab based on results from the TULIP-SC trial. Positive results were announced from a phase 3 study evaluating subcutaneous (SC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback